海燕药业

公司简介： 扬子江药业集团北京海燕药业有限公司成立于2004年2月，是扬子江药业集团在北方*的研发生产型全资子公司，公司位于北京市昌平区中关村生命科技园，占地64978.96平方米，建筑面积38258平方米，是北京市科委认定的高新技术企业、北京市发改委高新技术成果转化基地。 北京海燕药业是药物研发、药品生产、产品推广于一体的综合型企业，拥有3000多平米的实验室布局和完善的实验仪器及设备。已通过国家食品药品监督管理局大小容量注射剂、冻干粉针、口服固体制剂GMP认证。目前公司已上市品种主要有苏黄止咳胶囊、科苏、莫妮卡等，其中苏黄止咳胶囊是全国*批准治疗感冒后咳嗽及咳嗽变异性哮喘的纯中药制剂。 北京海燕药业的紫杉醇多聚谷氨酸偶合物候选药物研究课题或科技部重大新药创制专项资金扶持；降血脂新药烟酸洛伐他汀双层缓释片的研究开发获北京市科委高成长专项资金扶持；硝苯地平等通用名药物研发获得北京市科委“重大通用名药物研发”资金扶持；三类新药项目苯甲酸利扎曲普坦片，被发改委认定为重大科技成果转化项目，获得了免税的企业优惠政策；苏黄止咳胶囊IV期临床试验及扩大生产项目获得国家重大专项资金扶持。 北京海燕药业始终秉承集团“求索进去、护佑众生”的企业理念，坚持“自主经营、自负盈亏、自创品牌、自我发展”的16字方针目标，做好扬子江药业集团在北方的“窗口”作用。 Profile of Beijing Haiyan Pharmaceutical Company Beijing Haiyan Pharmaceutical Company in Beijing Life Science Park is a wholly owned subsidiary of Yangzi river Pharmaceutical Group which invested near 0.3 billion RMB. It occupies 65 thousmeter square. It is involved in drug research development, drug producing, selling registration. Now there is around 300 staff. The company was award of high technology company by Beijing science committee. In 2015, the sales target of the company is 2.5 billion RMB. The company’s R&D department consists of biological, chemical, Chinese medicine parts. Presently the company has 60 staff in R&D, 31projects, which will be marketed in the next seven years. Especially, the biomedicines products are selling from 2016. Now the company has already achieved six new products clinical program approved by SFDA. In R&D filed, majof new projects are settled by company UNISPAR.